"This happens to be a very exciting time," said Dr. David Reuben, director of the UCLA Alzheimer's and Dementia Care program.

Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (l ...

A new Alzheimer’s Association study found that exercise, a healthy diet, cognitive training and support from an ...